Corrigendum

The Review article by V Abitbol et al., ‘Navigating adalimumab biosimilars: an expert opinion’, which appeared in the November 2023 issue of the Journal of Comparative Effectiveness Research 12(11), e230117 (2023), was published with errors in Table 1.

Table 1. . Characteristics of Humira^® formulations and adalimumab biosimilars.

	Humira®	Humira® (citrate free)	Amgevita®/Amjevita®	Imraldi®/Hadlima®	Hyrimoz®	Hulio®	Idacio®	Amsparity®	Yuflyma®	Hukyndra®
EU/US market†	EU/US	EU/US	EU/US‡	EU/US	EU/US	EU	EU	EU	EU/US	EU
Needle size (G) syringe	27	29	29	29	27	29	29	29	29	29
Needle size (G) pen	27	29	27	29	27	29	29	29	29	29
Pre-filled syringe/pen	40 mg/-	20 mg, 40 mg, 80 mg/ 40 mg, 80 mg	20 mg, 40 mg/40 mg	40 mg/ 40 mg	20 mg, 40 mg, 80 mg/ 40 mg, 80 mg	20 mg, 40 mg/ 40 mg	40 mg/ 40 mg	20 mg, 40 mg/40 mg	40 mg, 80 mg/ 40 mg, 80 mg	40 mg, 80 mg/ 40 mg
Citrate	Yes	No	No	No§	No	No	Yes	No	No	No
Latex	Yes	No	Yes	No	No	No	No	No	No	No
Volume (ml) for 40 mg dose	0.8	0.4	0.8	0.4	0.4	0.8	0.8	0.8	0.4	0.4
Availability of 80 mg formulation	No	Yes (since 16 Dec 2021)	No	No	No	No	No	No	Yes	Yes (syringe only)
Shelf life at 25°C, days	14	14	14	31	21	14 (20 mg in 0.4 ml sterile solution), 56 (40 mg in 0.8 ml sterile solution)	28	30 (at 30°C)	31	14

^†As at 4 July 2023.

^‡High-concentration formulation expected to reach US market in 2024.

^§Imraldi^®/Hadlima^® has been citrate-free since the beginning of 2023.

The table included ‘Yes’ in the ‘Citrate’ row for Imraldi^®/Hadlima^®. However, the formulation has been citrate-free since the beginning of 2023.

In addition, in ‘Availability of 80 mg formulation’ row for Humira^® (citrate free), the text was included as ‘Yes (pen only)’. However, it should have read ‘Yes (since 16 Dec 2021)’.

These points have now been corrected.

The authors and editors of the Journal of Comparative Effectiveness Research would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.